Resverlogix Announces Ninth Positive Data Safety Monitoring Board Recommendation for Phase 3 Study of Apabetalone

Resverlogix Corp.

BETonMACE trial to continue as planned without modification CALGARY, Alberta, March 27, 2019 (GLOBE NEWSWIRE) — Resverlogix Corp. (“Resverlogix” or the “Company”) (TSX:RVX) today announces the independent Data and Safety Monitoring Board (DSMB) has completed a ninth planned safety review for the Company’s Phase 3, BETonMACE trial for high-risk cardiovascular disease patients and recommended the study continue without modification. The…

Read More